Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (5101)	12/11/2001 11:44:44 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Extra Pale, It's always tricky to compare across trials. Based on what little we know they seem fairly comparable. Given that their modes of actions (at least on the surface) appear quite different, there's a good chance they'd be used in combination. MM is not a huge indication (around 14k new cases a year), but if the new drugs can keep people alive longer, then the patient population will grow over time. Last figures I saw, 5 year survival was still under 30%. It's a very expensive disease to treat because bone-marrow transplants are fairly common (and sometimes repeated). Peter